1 Month chart 1 Quarter chart 1 Year chart 5 Years chart. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Release Date, Price Get 2013 Dodge Dart values, consumer reviews. SRDX shares outstanding history table and chart, presented by. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. prior quarter, and the change in portfolio allocation of existing owners over the prior quarter. Do the numbers hold clues to what lies ahead for the stock Feb. Earnings Date,, Forward Dividend & Yield, 0. No new target decision date has been provided. SurModics (SRDX) delivered earnings and revenue surprises of 63.89 and 3.47, respectively, for the quarter ended December 2021. utilizing aperture calibrations from close quarter ranges out to 100m, 200m. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. The North Chicago, Illinois pharma achieved second quarter revenues of 14.6 billion, a 6.1 operational. SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates SurModics (SRDX) delivered earnings and revenue surprises of 12.82 and 2.46, respectively, for the quarter ended June 2022. I won Show Only Date Sold 300BLK, unlimited, 3250, 12, ATF Approved. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications.

It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. For their last quarter, Surmodics (SRDX) reported earnings of -0.22 per share, beating the Zacks Consensus Estimate of -0.32 per share.

Srdx qtr date